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Abstract
Background: Phosphatidylinositol phosphates (PIPs) are low-abundance phospholipids that participate in a range of
cellular processes, including cell migration and membrane traffic. PIP levels and subcellular distribution are regulated
by a series of lipid kinases and phosphatases. In skeletal muscle, PIPs and their enzymatic regulators serve critically
important functions exemplified by mutations of the PIP phosphatase MTM1 in myotubular myopathy (MTM), a
severe muscle disease characterized by impaired muscle structure and abnormal excitation–contraction coupling.
FIG4 functions as a PIP phosphatase that participates in both the synthesis and breakdown of phosphatidylinositol
3,5-bisphosphate (PI(3,5)P2). Mutation of FIG4 results in a severe neurodegenerative disorder in mice and a progressive
peripheral polyneuropathy in humans. The effect of FIG4 mutation on skeletal muscle has yet to be examined.
Methods: Herein we characterize the impact of FIG4 on skeletal muscle development and function using the
spontaneously occurring mouse mutant pale tremor (plt), a mouse line with a loss of function mutation in Fig4.
Results: In plt mice, we characterized abnormalities in skeletal muscle, including reduced muscle size and specific
force generation. We also uncovered ultrastructural abnormalities and increased programmed cell death. Conversely,
we detected no structural or functional abnormalities to suggest impairment of excitation–contraction coupling, a
process previously shown to be influenced by PI(3,5)P2 levels. Conditional rescue of Fig4 mutation in neurons
prevented overt muscle weakness and the development of obvious muscle abnormalities, suggesting that the
changes observed in the plt mice were primarily related to denervation of skeletal muscle. On the basis of the ability
of reduced FIG4 levels to rescue aspects of Mtmr2-dependent neuropathy, we evaluated the effect of Fig4
haploinsufficiency on the myopathy of Mtm1-knockout mice. Male mice with a compound Fig4+/−/Mtm1–/Y genotype
displayed no improvements in muscle histology, muscle size or overall survival, indicating that FIG4 reduction does
not ameliorate the Mtm1-knockout phenotype.
Conclusions: Overall, these data indicate that loss of Fig4 impairs skeletal muscle function but does not significantly
affect its structural development.
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Background
Phosphatidylinositol phosphates (PIPs) are low-abundance
phospholipids that are implicated as regulators of a
range of cellular processes, including cell migration,
subcellular organelle trafficking and autophagy [1,2].
Phosphatidylinositol 3,5-bisphosphate, or PI(3,5)P2, is a
low-abundance PIP whose function has recently come into
focus [3]. PI(3,5)P2 is generated by the action of PIKfyve,
a five-position phosphoinositide kinase [4]. PI(3,5)P2 is
metabolized by FIG4 (Sac3), a five-position phosphoino-
sitide phosphatase, to regenerate phosphatidylinositol 3-
phosphate (PI(3)P), and by myotubularins, a family of
three-position phosphatases to generate phosphatidy-
linositol 5-phosphate (or PI(5)P) [5-8]. Of note, maximal
function of PIKfyve requires a complex of proteins that in-
cludes VAC14 and FIG4 [9-11]. Reduced abundance of
FIG4 protein destabilizes PIKfyve, resulting in a threefold
reduction of PI(3,5)P2 relative to total PI levels [12].
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We recently identified and characterized a spontan-
eous mouse mutant (“pale tremor” or plt) with a homo-
zygous recessive loss-of-function mutation in the Fig4
gene [12]. plt mice exhibit severe and progressive neuro-
degeneration that involves both neurons and glia of the
central and peripheral nervous system [13]. The main
subcellular phenotype is increased vacuolization due to
defective lysosomal function and impaired autophagy
[14,15]. In addition, we (the Meisler group) have identi-
fied recessive FIG4 mutations in patients with hereditary
peripheral neuropathy (Charcot-Marie-Tooth Disease
type 4J) [16-18] and motor neuron disease (amyotrophic
lateral sclerosis, or ALS) [19]. However, the role of FIG4
in skeletal muscle has yet to be extensively examined
in detail.
Studies of myotubularins indicate a potentially import-
ant role for PI(3,5)P2 regulation in skeletal muscle
[20-22]. The mammalian myotubularin gene family con-
tains 15 members encoding phosphatases that primarily
dephosphorylate PI(3)P and PI(3,5)P2 [23]. Mutation of
MTM1, the canonical member of this gene family, results
in increased levels of PI(3)P, and possibly PI(3,5)P2, in skel-
etal muscle and causes myotubular myopathy (MTM), a
severe congenital muscle disease associated with altered
muscle structure and profound muscle weakness [24]. Mu-
tation of MTM1 compromises multiple aspects of muscle
function [25], most notably excitation–contraction coup-
ling (EC coupling) [26], the process by which neuronal
stimulation to muscle is translated into calcium-dependent
muscle contraction. Specifically, MTM1 mutations lead to
severe abnormalities in the structure of the EC coupling
machinery [27].
MTMR14 is another myotubularin family member that
is important for muscle function [26]. Loss of MTMR14
function in zebrafish and mice causes aberrant autoph-
agy and impaired EC coupling [26,28]. Unlike MTM1,
loss of MTMR14 alters EC coupling without significantly
changing the underlying structure of the EC coupling
machinery. Direct application of PI(3,5)P2 increases cal-
cium release from microsomes containing the intracellu-
lar ryanodine receptor 1 calcium release channel (RyR1),
a critical component of the EC coupling apparatus. Thus,
direct regulation of RyR1-dependent stimulated calcium
release may represent one important role of PI(3,5)P2 and
MTMR14 [29].
Given the potential importance of PI(3,5)P2 in skeletal
muscle, we sought to understand the impact of FIG4
mutation on muscle development and homeostasis. To
address this issue, we examined skeletal muscle structure
and function in the plt-null mouse model of FIG4
dysfunction. We examined plt mice, which die before 2
months of age as a result of progressive neurodegeneration,
as well as plt mice with restored FIG4 expression in neu-
rons [12,15]. The latter mice have no overt phenotype and
survive for more than 18 months. Our data reveal that Fig4
mutation is associated with skeletal muscle changes (atro-
phy and increased apoptosis) and impaired muscle force
generation, but not with abnormalities in the structure or
function of the EC coupling machinery. The changes are
likely the consequence of impaired neuronal input because
phenotypic rescue is largely provided by neuronal expres-
sion of FIG4. In addition, we found that haploinsufficiency
of Fig4 does not ameliorate effects of Mtm1 mutation in
muscle, in contrast to a previous report that haplo-
insufficiency of Fig4 rescues the neuropathy associated with
Mtmr2 mutation [30,31]. Together, our results support a
requirement for FIG4 in skeletal muscle function, but not
a cellular autonomous role in either muscle development
or EC coupling.
Methods
Animal care and husbandry
All animals were cared for per protocol under the guid-
ance of, and with ethical approval from, the University
Committee on Use and Care of Animals (UCUCA) and
with the assistance of members of the University of
Michigan’s Unit for Laboratory Animal Medicine (ULAM),
who carefully monitored the health of the rodent colonies.
ULAM maintained proper environmental regulation, in-
cluding temperature and light cycles, unlimited access to
water, appropriate food supply and clean enclosures. The
Fig4-null mutation plt is maintained on two congenic lines,
C57BL/6J.plt/+ (N14) and C3H.plt/+ (N10) [32]. Experi-
ments were carried out on homozygous plt/plt F1 mice
obtained from crosses between the two congenic strains.
Pups were weaned according to standard protocols, and
tails were clipped for genotyping.
Western blot analysis
Western blot analyses were performed using the follow-
ing antibodies: FIG4 (1:1,000 NeuroMab; UC Davis/NIH
NeuroMab Facility, Davis, CA, USA) and glyceraldehyde
3-phosphate dehydrogenase (1:1,000 GAPDH; Millipore,
Billerica, MA, USA). Mouse multitissue Western blot
antibody was obtained from IMGENEX (San Diego,
CA, USA). Protein extracts were established from flash-
frozen mouse skeletal muscle and brain using T-PER tis-
sue protein extraction reagent and a Dounce tissue
homogenizer (Pierce Biotechnology, Rockford, IL, USA).
Approximately 50 μg of protein were loaded per sample,
resolved by polyacrylamide gel electrophoresis on 11%
gels, and transferred to polyvinylidene fluoride. Second-
ary antibodies were used at 1:2,000 (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), blots were developed
using electrochemiluminescence reagent (GE Biosciences,
Pittsburgh, PA, USA), and bands visualized using the
Bio-Rad ChemiDoc XRS+ System illuminator (Bio-Rad
Laboratories, Hercules, CA, USA).
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Histopathology
Animals were killed by anesthetic injection, which was
followed by cervical dislocation. Tissues were then iso-
lated using sterile surgical methods without the use of
laminar flow hoods. Muscle tissue from quadriceps and
tibialis anterior muscles was dissected and mounted
onto small balsa wood pieces that had previously been
frozen with drops of Tissue-Tek O.C.T. compound (Sakura
Finetek USA, Torrance, CA, USA) and then semithawed
with light friction. The mounted muscle tissue was
immediately submerged in a −55°C isopentane bath
cooled by liquid nitrogen for flash-freezing.
Muscles were cut into 12-μm cross-sections and
mounted on Superfrost Plus slides (Thermo Scientific,
Waltham, MA, USA) using a Leica cryostat (Leica
Biosystems, Buffalo Grove, IL, USA) at −20°C and dried at
room temperature before storage at −80°C. Slides were
stained with Mayer’s hematoxylin and eosin (H&E) or suc-
cinate dehydrogenase (SDH) following standard protocols
and mounted with Permount mounting medium (Thermo
Scientific). Apoptotic fibers were visualized with the
ApopTag Plus Peroxidase In Situ Apoptosis Kit (S7101;
Chemicon International/EMD Millipore, Billerica, MA,
USA). Photomicrographs were captured using an INFIN-
ITY1 digital camera with eponymous software (Lumenera
Corp, Ottawa, ON, Canada) visualized through an Olym-
pus BX43 light microscope (Olympus America, Center
Valley, PA, USA).
Ultrastructural analysis
Immediately following dissection, quadriceps and gastro-
cnemius muscles were carefully cut into approximately
1-mm × 2-mm fragments and incubated in Karnovsky’s
fixative overnight at 4°C. Fixed tissue was brought to the
Microscopy and Imaging Laboratory (MIL) Core facility
at the University of Michigan for processing. Ultrathin
sections were analyzed for orientation, and grids were
prepared for use on the Philips CM-100 transmission elec-
tron microscope (Koninklijke Philips N.V., Amsterdam,
The Netherlands).
Myocyte isolation
Muscle was dissected from the shoulders and legs of dead
mice and placed immediately into sterile phosphate-
buffered saline. Muscle was then minced finely with a ster-
ile razor, fully dissociated with a mixture of collagenase
type I (0.1%) and trypsin (0.1%) in Ham’s F-12 medium,
then incubated at 37°C for approximately 1 h with periodic
trituration. Cells were pelleted and resuspended in 1:1
Dulbecco’s Modified Eagle Medium:Ham’s F-12 Nutrient
Mixture (DMEM/F-12) (Gibco/Life Technologies, Grand
Island, NY, USA) with 20% fetal calf serum (HyClone
Laboratories, Logan, UT, USA), then filtered through
70- and 40-μm meshes and plated onto collagen-coated
dishes (BD Biosciences, San Jose, CA, USA). Media were
changed after a 1-h incubation at 37°C, and recombinant
human fibroblast growth factor–basic (AA 10-155, Publi-
cation PHG0026; Gibco/Life Technologies) was added to
a final concentration of 10 ng/ml. Cells were maintained
at 37°C in a 5% CO2 atmosphere with daily changes
of fresh media. Cells were visualized using Hamamatsu
ORCA-R2 camera and software (Hamamatsu Photonics,
Hamamatsu-shi, Japan) on a Leica inverted microscope
(Leica Microsystems). All experimentwas were performed
on passages 2 through 4 myocytes. Terminal deoxynu-
cleotidyl transferase-mediated dUTP nick end labeling
(TUNEL) staining was performed per the manufacturer’s
recommendations on myocytes grown on coverglass
coated with fibronectin and fixed with 4% paraformalde-
hyde prior to staining.
Muscle force measurement
Extensor digitorum longus (EDL) and soleus muscles were
carefully isolated and removed from anesthetized mice.
Muscles were immediately placed into a bath of Krebs
mammalian Ringer solution with 0.25 mM tubocurarine
chloride maintained at 25°C and bubbled with 95% O2 and
5% CO2 to stabilize pH at 7.4. Using 5-0 silk suture, the
distal tendon of the muscle was attached to a servomotor
(model 305B; Aurora Scientific, Aurora, ON, Canada), and
the proximal tendon was attached to a force transducer
(model BG-50; Kulite Semiconductor Products, Leonia, NJ,
USA). Muscles were stimulated by square pulses delivered
by two platinum electrodes connected to a high-power bi-
phasic current stimulator (model 701B; Aurora Scientific).
A personal computer running custom-designed software
(LabVIEW 7.1; National Instruments, Austin, TX, USA)
controlled electrical pulse properties and servomotor activ-
ity and recorded data from the force transducer. Stimula-
tion voltage and optimal muscle length (Lo) were adjusted
to give maximum twitch force [33]. While held at Lo, mus-
cles were subjected to trains of pulses 300 ms in duration
for EDL muscles and 900 ms for soleus muscles, with in-
creasing stimulation frequency until maximum isometric
tetanic force (Po) was achieved [33]. Lo was measured with
digital calipers, and muscle fiber lengths (Lf ) were deter-
mined by multiplying Lo by previously established Lf-to-Lo
ratios of 0.44 for EDL muscle and 0.71 for soleus muscle
[33]. Total muscle fiber cross-sectional area (CSA) was es-
timated by dividing the mass of the muscle by the product
of Lf and 1.06 g/cm
3, the density of mammalian skeletal
muscle. Po was normalized by CSA to give specific Po.
Simultaneous measurement of macroscopic L-type Ca2+
currents and voltage-gated Ca2+ transients in myotubes
Primary cultures of skeletal myotubes were generated from
myoblasts derived from wild-type (WT) and plt mice as
previously described [34]. The whole-cell voltage-clamp
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technique in conjunction with a Ca2+-sensitive dye (fluo-4)
was used to simultaneously measure voltage-gated L-type
Ca2+ currents (L-currents) and intracellular Ca2+ transients
on individual myotubes from 8- to 11-day-old myotube
cultures [34,35]. All voltage-clamp experiments were car-
ried out after an approximately 5-min period of dialysis
following establishment of the whole-cell configuration.
The external recording solution consisted of 145 mM
tetraethylammonium chloride, 10 mM CaCl2 and 10 mM
2-[4-(2-hydroxyethyl)piperazine-1-yl]ethanesulfonic acid
(HEPES) (pH 7.4). The internal patch pipette solution
consisted of 145 mM Cs-aspartate, 10 mM CsCl, 0.1 mM
Cs2-ethylene glycol tetraacetic acid, 1.2 mM MgCl2, 5 mM
Mg-ATP, 0.2 mM K5-fluo-4 and 10 mM HEPES (pH 7.4).
A 1-s prepulse to −30 mV delivered immediately before
each test pulse was used to inactivate voltage-gated
Na+ and T-type Ca2+ channels without producing sig-
nificant L-channel inactivation. L-currents and Ca2+ release
were subsequently elicited by 200-ms test depolarizations
from −50 mV to +70 mV in 10-mV increments and a 10-s
interval between each test pulse. Capacitative currents
were minimized to about 10% using the capacitance can-
celation feature of the patch-clamp amplifier. Remaining
linear components were leak-subtracted using a P/3 proto-
col delivered from a holding potential of −80 mV before
each test pulse. Peak L-current magnitude was normalized
to cell capacitance (pA/pF), which was plotted as a func-
tion of membrane potential (Vm) and fitted as I = Gmax
(Vm – Vrev)/(1 + exp[(VG1/2 – Vm)/kG]), where Gmax is the
maximal L-channel conductance, Vm is test potential, Vrev
is extrapolated reversal potential, VG1/2 is the voltage for
half-maximal activation of Gmax, and kG is a slope factor.
Relative changes in intracellular Ca2+ during each test
depolarization were measured following dialysis with K5-
fluo-4 salt. Fluo-4-dialyzed myotubes were excited at 480
nm and fluorescence emission measured at 535 nm was
digitized at 10 kHz. A computer-controlled shutter was
used to eliminate dye illumination during intervals be-
tween each test pulse. Relative peak changes in intracellular
Ca2+ were expressed as ΔF/F ([Fpeak – Fbase]/Fbase) at the
end of each test pulse, plotted as a function of Vm, and fit-
ted according to the equation ΔF/F = (ΔF/Fmax)/{1 + exp
[(VF1/2 – Vm)/kF]}, where (ΔF/F)max is the calculated
maximal change in fluorescence, VF1/2 is the voltage for
half-maximal activation of (ΔF/F)max, and kF is a slope
factor. Pooled current-voltage (I-V) and fluorescence-
voltage (ΔF/F-V) data were expressed as means ± SEM.
Statistical significance was determined using a two-tailed
Student’s t-test.
Statistical analyses
GraphPad Prism software (GraphPad Software, La Jolla,
CA, USA) was used to calculate the significance of fiber
size differences and TUNEL staining results with unpaired
Student’s t-tests and one-way analysis of variance with
Tukey’s post hoc multiple comparison test.
Results
FIG4 is expressed in skeletal muscle
We wanted to establish that FIG4 protein was present
in skeletal muscle. We therefore performed Western
blot analysis using anti-FIG4 antibody (NeuroMab). We
first used a premade multitissue Western blot antibody
(IMGENEX) and found that FIG4 was present in most
tissues examined, including skeletal muscle (Figure 1A).
To determine if FIG4 expression was regulated with mat-
uration of skeletal muscle, we examined protein extracts
from skeletal muscle of various postnatal ages (Figure 1B)
as well as from differentiating C2C12 myocytes (Figure 1C).
We detected no obvious variability in FIG4 levels at
Figure 1 FIG4 is expressed in skeletal muscle. Western blot
analysis was performed to establish FIG4 expression using anti-FIG4
antibody. (A) Mouse multitissue Western blot reveals expression of
FIG4 in a variety of tissues (Br = brain, Ht = heart, SmI = small
intestine, Kid = kidney, Liv = liver, Lg = lung, SkM = skeletal muscle,
St = stomach, Spl = spleen, Ov = ovary, Tes = testis). (B) FIG4 is
expressed at multiple mouse ages in brain and skeletal muscle. Ages
of mice tested were 1, 3, 6, 9 and 20 months. Left lanes are from
brain, and right lanes are from quadriceps. The top blot was probed
with anti-FIG4, and the bottom blot (loading control) was probed with
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). (C) Western blot
of protein extracts from C2C12 cells at various stages of differentiation.
Differentiation was induced by serum withdrawal. Cells were
differentiated until long myotubes were obviously present (day 8 = D8).
(D) Analysis of wild-type littermate and pale tremor (plt) mouse skeletal
muscle reveals that FIG4 is absent from plt muscle.
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different mouse ages or different developmental stages
in vitro; thus we conclude that FIG4 is a ubiquitously
expressed component of skeletal muscle. Of note, we
verified that FIG4 expression was absent in Fig4-null (that
is, plt) skeletal muscle as compared to WT littermates
(Figure 1D).
Fig4-null myofibers are reduced in size and exhibit
ultrastructural abnormalities
We began our analysis by examining both light and elec-
tron microscopic features of skeletal muscle from Fig4-
null mice. We examined muscle at 5 weeks of age, since
these mice do not survive beyond 6 weeks of age [32].
We also studied a limited number of animals with ex-
pression of a Fig4 cDNA transgene under control of the
neuron-specific enolase (NSE) promoter [15]. These ani-
mals were examined at 4, 8 and 20 months of age.
Routine histopathological analysis of quadriceps, gastro-
cnemius and diaphragm using H&E and SDH stains did
not reveal any obvious abnormalities in plt skeletal muscle
compared to the WT (Figures 2A through 2D). However,
the CSA of pltmyofibers was significantly smaller than that
of their WT counterparts. Quantitation of cross-sectional
fiber area revealed that plt myofibers were 55.3% smaller
than WT fibers (n = 400 total fibers counted from quadri-
ceps in three mice per condition) (Figure 2E). This reduc-
tion in size corresponds with the observation that overall
quadriceps weight in plt animals was similarly significantly
reduced compared to that of age-matched WT littermates
(Additional file 1: Figure S1). Of note, overall body weight
(which is largely dictated by muscle weight) at 6 weeks of
age was also significantly reduced in plt mice (Additional
file 1: Figure S2).
Ultrastructural analyses were performed on quadriceps
muscle from age-matched WT and plt mice using trans-
mission electron microscopy (n = 4 per condition).
Overall, muscle ultrastructure in plt mice resembled that
of controls (Figures 3A and 3B), though swollen and en-
larged mitochondria were occasionally observed in muscle
from plt mice (M in Figure 3C). We did not, however, de-
tect consistent abnormalities in the triad, the location of
the EC coupling machinery, in any plt mouse examined
(arrow in Figure 3B).
Increased apoptosis in skeletal muscle and primary
myocytes from Fig4-deficient mice
The combination of reduced muscle fiber size and ul-
trastructurally abnormal mitochondria led us to exam-
ine whether there was increased cell death in plt
muscle. TUNEL staining of muscle sections revealed
few positive cells in the WT tissue but several positive
cells in the mutant tissue (Figure 4A). To better evalu-
ate this finding, we studied isolated myocytes from neo-
natal WT and plt mice. As with primary cells from other
organ systems of the plt mice, cells derived from plt
muscle demonstrated abundant vacuolization (Additional
file 1: Figure S3). We measured cell death in these pri-
mary cell cultures using a TUNEL assay. We observed a
significant increase in TUNEL-positive cells in Fig4-
mutant myocytes, consistent with decreased cell sur-
vival (Figure 4B). Of note, despite the vacuolization and
impaired survival, Fig4-null myocytes were able to suc-
cessfully differentiate into myotubes upon serum with-
drawal (data not shown). There was also no change
in the ability of plt myocytes to proliferate, as deter-
mined by bromodeoxyuridine (BrdU) labeling of cells
(64% of cells BrdU-positive in control (116 of 182 cells
counted) vs 64% of cells positive in plt (151 of 235
cells counted).
Figure 2 Histopathological analysis of pale tremor (plt) skeletal
muscle. Hematoxylin and eosin staining (A) and (B) and succinate
dehydrogenase staining (C) and (D) of cryosections from quadriceps
of control (wild-type (WT)/littermate (LM)) and plt animals. Scale
bars = 50 μm. (E) Quantitation of myofiber size from quadriceps muscle
of 4-week-old plt and WT animals. There were significant reductions in
myofiber size: 2,649 μm2 ±70 for WT vs 1,185 μm2 ± 32 for plt (n = 400
per condition, P < 0.0001).
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FIG4-mutant skeletal muscle has impaired force
generation
To determine the potential functional effects of Fig4 de-
ficiency in skeletal muscle, we measured force gener-
ation from intact muscle fibers. Testing both EDL and
soleus muscles revealed statistically significant reduc-
tions in specific force generation (12% to 24% decrease
when adjusted for CSA), indicating mild muscle weak-
ness and impaired force generation in the plt animals
(Figure 5).
FIG4-mutant myocytes have normal intracellular calcium
dynamics
Given the previous association between PI(3,5)P2 and
EC coupling and the fact that FIG4 is a known regulator
of PI(3,5)P2 levels, we interrogated intracellular calcium
dynamics. We used whole-cell voltage patch-clamping of
isolated neonatal mouse myocytes to simultaneously meas-
ure voltage-gated L-type calcium currents and intracellular
calcium transients. We did not detect abnormalities
in either orthograde or retrograde coupling or in L-type
Figure 3 Ultrastructural analysis of pale tremor (plt) skeletal muscle. Representative photomicrographs from transmission electron
microscopic analysis of wild-type/littermate (WT) quadriceps (A) and plt quadriceps (B) and (C). Muscle ultrastructure was generally normal in plt
muscle (B) with evidence of normal triads (arrow). There were infrequently observed areas of abnormalities that particularly included swollen
and/or dilated mitochondria (M in (C)). Scale bars = 500 nm.
Figure 4 Increased apoptosis in plt skeletal muscle and skeletal myocytes. (A) Terminal deoxynucleotidyl transferase-mediated dUTP nick
end labeling (TUNEL) staining was performed on sections from wild-type (WT) and plt skeletal muscle. Arrows point to TUNEL-positive nuclei.
There was a qualitative increase in TUNEL-positive fibers in plt muscle (experiment repeated with sections from three different mice per
condition). (B) TUNEL staining was performed on myocytes. There was a significant increase in TUNEL-positive cells in plt myocytes vs WT
myocytes. Data reflect fraction of 4′,6-diamidino-2-phenylindole-positive nuclei that were also TUNEL-positive. Numbers were 0.28 ± 0.06 for plt
and 0.17 ± 0.05 for WT (P = 0.006). One hundred cells per experiment were counted, and each experiment was repeated five times (once for
each culture derived with cells isolated from five different mice per condition).
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calcium currents in plt myocytes (Figure 6 and Table 1).
Taken in conjunction with the normal histological ap-
pearance of the triad, these data suggest that loss of Fig4
is not associated with impaired bidirectional dihydro-
pyridine receptor (DHPR)–RyR1 coupling.
Neuronal expression of Fig4 in plt mice reduces skeletal
muscle pathology
We previously reported that expression of FIG4 under
the NSE promoter in plt animals prevents the develop-
ment of typical phenotypic abnormalities [15]. In fact,
the appearance of the transgenic (Tg) animals is indistin-
guishable from their WT littermates. We examined skeletal
muscle in Fig4−/−/TgNSE mice at 4, 8 and 20 months of
age. There was no obvious difference in histological ap-
pearance between WT and Fig4−/−/TgNSE mice, which is
similar to what we observed in the Fig4-null mice. Unlike
the null mice, however, Fig4−/−/TgNSE mice exhibited only
a very slight alteration in myofiber size (11% smaller
than WT; n = 5 animals examined per genotype, P = 0.02)
(Figures 7A and 7B). This reduction was statistically sig-
nificant and occurred despite the fact that overall weight
was the same between WT and Fig4−/−/TgNSE animals.
Fig4−/−/TgNSE muscle did not display any of the ultra-
structural changes seen in the Fig4−/− mice (Figure 7C) and
did not exhibit evidence of increased apoptosis.
Last, to determine whether muscle function was altered
in Fig4−/−/TgNSE mice, we measured maximum isometric
force in soleus and EDL muscles of 18-month-old animals.
There was a small (approximately 10%) but statistically in-
significant (P > 0.1) decline in force generation between
Fig4−/−/TgNSE mice and their WT littermates (Additional
file 1: Figure S4). Taking all our data together, we conclude
that expression of Fig4 in neurons is sufficient to correct
the development of significant muscle atrophy and pro-
grammed cell death in plt skeletal muscle, but not to
Figure 5 Diminished force production in pale tremor (plt) skeletal muscle. Specific force (normalized to muscle and body weight) was
measured for wild-type/littermate (WT) and plt (mutant) skeletal muscle (left panel = extensor digitorum longus, or EDL) (right panel = soleus).
Normalized force was significantly reduced in plt muscles (n = 7 animals tested per condition). *P = 0.043 for EDL and P < 0.001 for soleus.
Figure 6 L-currents and voltage-gated Ca2+ release are unaltered in pale tremor (plt) myotubes. (A) Representative whole-cell L-type
Ca2+ currents (ICa) and intracellular Ca
2+ transients (ΔF/F) obtained following 200-ms depolarizations to the indicated membrane potentials in
myotubes derived from either wild-type (WT) mice (upper panel) or plt mice (lower panel). (B) and (C) Average (±SEM) voltage dependence of
peak L-type Ca2+ current density (B) and intracellular Ca2+ transients (C) for myotubes derived from either WT mice (filled circles) or plt mice
(open circles).
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prevent subtle but reproducible changes in myofiber size
in vivo. Of note, we verified by both RNA (reverse tran-
scriptase polymerase chain reaction) and Western blot
analysis that there was no appreciable Fig4 RNA or pro-
tein in muscle of Fig4−/−/TgNSE mice (data not shown
and Figure 1D).
Fig4 haploinsufficiency does not improve the
Mtm1-knockout mouse phenotype
There is a complex interplay between the enzymes that
regulate phosphoinositides. One potential avenue for
treatment of diseases related to PIP dysregulation is ma-
nipulation of other enzyme levels. This point has been
demonstrated for the neurological abnormalities associated
with Mtmr2 mutation [30]. Mice with a recessive mutation
in Mtmr2 exhibit peripheral neuropathy, and aspects of
this neuropathy are reversed in the setting of Fig4
haploinsufficiency. Since MTM1 and MTMR2 are highly
homologous, we evaluated the effect of haploinsufficiency
of Fig4 (in plt+/− mice) on the severe muscle phenotype in
knockout mice lacking expression of Mtm1. Generation of
Fig4+/−/Mtm1–/Y male mice revealed no difference from
Mtm1–/Y mice, with comparable impairments of weight
gain, motor function and survival and no statistically
significant difference in weight or survival (Figures 8A
and 8B).
By histopathological analysis, we demonstrated similar
alterations between Mtm1–/Y mice and Mtm1–/Y/Fig4+/−
mice. We quantitated myofiber size because size is corre-
lated with disease severity in patients with MTM [36].
There was no clear difference in this parameter (Figure 8B,
consistent with the observed lack of functional improve-
ment in the Fig4+/–/Mtm1–/Y animals. In all, haploinsuffi-
ciency of Fig4 did not appear to alter the Mtm1 phenotype
in any meaningful way.
Discussion
FIG4 exhibits an important role in central and peripheral
nervous system development and homeostasis. The conse-
quences of FIG4 deficiency on other organ systems are less
well delineated. In this study, we defined the consequences
of Fig4-null mutation on skeletal muscle. We found that
(1) global inactivation of Fig4 in the plt mouse is associated
with myofiber atrophy and/or hypotrophy, increased apop-
tosis and diminished specific force production; (2) loss of
Fig4 does not alter the structure, EC coupling apparatus or
bidirectional DHPR–RyR1 coupling; and (3) reexpression
of Fig4 in neurons significantly reduces all observed muscle
Table 1 Parameters of fitted current-voltage and fluorescence-voltage (ΔF/F-V) curvesa
Gmax (nS/nF) VG1/2 (mV) kG (mV) VREV (mV) (ΔF/F)max VF1/2 (mV) kF(mV)
WT (n = 11) 219 ± 14 9.8 ± 1.4 5.0 ± 0.5 65.3 ± 3.0 2.3 ± 0.4 −7.8 ± 1.9 4.4 ± 0.2
plt (n = 11) 194 ± 15 9.4 ± 1.3 4.0 ± 0.4 66.7 ± 2.7 2.1 ± 0.2 −5.8 ± 1.7 4.6 ± 0.3
aWT wild type.
Figure 7 Transgenic (Tg) neuronal rescue of FIG4 expression largely restores plt myofiber size. (A) Hematoxylin and eosin–stained sections of
gastrocnemius muscle from wild-type (WT) and Fig4−/−/NSE-FIG4 (that is, plt with transgenic expression of Fig4 driven by the neuron-specific enolase
(NSE) promoter). The plt muscle is essentially indistinguishable from WT, with the exception of mild reduction in fiber size. (B) Quantification of myofiber
size from quadriceps muscles of 8-month-old Fig4−/−/NSE-FIG4 and WT animals. There was a small but significant reduction in total fiber area in
transgenically rescued plt muscle: 2,799 μm2 ± 165 for WT vs 2,322 μm2 ± 121 for plt (n = 60, P = 0.02). (C) Transmission electron photomicrographs from
tibialis anterior muscle. Normal triads and mitochondria were present in both WT and plt/Tg-NSE-Fig4 animals.
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abnormalities. The implications of these findings are
discussed below.
Perhaps the most striking aspect of this study is the
fact that Fig4 mutation did not result in a more deleteri-
ous direct effect on muscle development and function.
In neurons and glia, loss of FIG4 results in severe struc-
tural and functional consequences. Given the previously
recognized importance of phosphoinositide regulation in
skeletal muscle [26,27], we predicted that plt mice would
exhibit pronounced changes in muscle structure and
function. However, effects of Fig4 ablation on muscle were
minimal and largely rescued following neuron-specific res-
toration of FIG4 expression (Fig4−/−/TgNSE mice). Muscle
alterations found to persist in Fig4−/−/TgNSE mice (for
example, 11% reduction in fiber size) could be explained
by either a minor role for FIG4 expression in muscle fiber
size determination or a small amount of residual neuro-
genic atrophy. It is of interest to note the dichotomy be-
tween the relatively normal appearance of adult plt muscle
in situ and the extensive vacuolarization of plt myocytes
in vitro. Similar effects of culturing have been observed in
other cell types, including fibroblasts [12] and osteoblasts
Figure 8 Fig4 haploinsufficiency does not improve the Mtm1-knockout phenotype. (A) Hematoxylin and eosin stain of quadriceps muscle
from wild-type (WT; plt+/−) (top), Mtm1-knockout (Mtm1-KO) (SM, middle) and plt+/−/Mtm1-KO (DM, bottom) animals. There was no obvious
difference in the appearance of the muscle or in the number of abnormal fibers (arrows). (B) Distribution of fiber area. Fiber area was measured
from WT; plt+/−), single-mutant (SM; Mtm1-KO) and double-mutant (DM; plt+/−/Mtm1-KO) skeletal muscles. Thirty fibers from each animal were
measured (n = 4 for SM and DM, n =2 for WT). (C) Terminal body weight (measured in grams). There was significant reduction in the Mtm1-KO
body weight compared to WT. There was no improvement in body weight in plt+/−/Mtm1-KO animals. Average values were as follows: 17.8 ± 0.6 g
for WT (n = 8), 11.4 ± 0.7 g for Mtm1-KO (n = 9, P < 0.0001 compared to WT) and 10.5 ± 0.9 g for plt+/−/Mtm1-KO (n = 5, P = 0.48 compared to
Mtm1-KO). (D) Haploinsufficiency of Fig4 did not provide any survival benefit. Average survival was 32 ± 2 days for Mtm1-KO (n = 9) and 31 ± 3
days for plt+/−/Mtm1-KO (n = 5).
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(unpublished manuscript, Lenk GM and Meisler MH). The
explanation for this difference is unclear and requires fur-
ther experimentation.
There are several potential explanations for the lack of
a more severe phenotype in skeletal muscle of Fig4-null
mice. First of all, the partial reduction of PI(3,5)P2 likely
caused by loss of Fig4 may not be enough to result in
significant consequences for muscle development and
function. Alternatively, a different PIKfyve protein complex
may compensate for the loss of FIG4 to provide sufficient
levels of PI(3,5)P2 to maintain myofiber homeostasis.
A third possibility is that PI(3,5)P2 may be generated in
muscle by a different or complementary pathway. For ex-
ample, a three-position kinase may generate PI(3,5)P2
from PI(5)P. One current barrier to attempting to distin-
guish these possibilities is the lack of suitable approaches
to measure PI(3,5)P2 in whole tissues such as skeletal
muscle. Development of techniques to aid in measuring
PI(3,5)P2 in situ are required to answer these questions
more definitively.
Regardless of the explanation, the fact that there is lit-
tle, if any, muscle-cell autonomous phenotype in Fig4-
null animals indicates that FIG4 mutations are unlikely
to result in primary muscle disease. However, significant
secondary neurogenically mediated myopathic features,
such as those observed in plt mice, including reduced
muscle fiber CSA and specific force generation, suggest
that skeletal muscle changes may contribute to disease
pathogenesis. In other words, the myopathic changes de-
scribed herein may influence disease severity in patients
with Charcot-Marie-Tooth disease type 4J and other dis-
orders caused by FIG4 gene mutation.
The lack of impairment in the structure of the EC
coupling apparatus or of bidirectional triad coupling in
Fig4-null mice was unexpected. Data from the MTMR14-
knockout mice support the hypothesis that increased levels
of PI(3,5)P2 impair calcium release from the ryanodine re-
ceptor (the core component of the EC apparatus), though
the underlying mechanism is not clear. Our data imply that
reduced levels of PI(3,5)P2 do not acutely impair voltage-
gated triad calcium release. Furthermore, the chronic loss
of FIG4 from muscle (with the potential implication of
chronically reduced PI(3,5)P2 levels) does not alter the ul-
trastructural appearance of the triad (that is, the location
of the EC coupling machinery). Thus, a requirement for
normal levels of PI(3,5)P2 for EC coupling seems unlikely,
though the present data do not completely exclude this
possibility. In addition to more direct interrogation of EC
coupling in FIG4-deficient mice, another potential future
direction to address this issue would be to assess the
impact on EC coupling of muscle-specific knockout of
PIKfyve, the kinase required for PI(3,5)P2 generation.
Again, however, this would necessitate confirmation of a
specific reduction in PI(3,5)P2 levels in skeletal muscle.
The final significant observation in this study is that
reduced Fig4 expression via plt haploinsufficiency does
not significantly alter the phenotype of Mtm1-knockout
mice. Of note, the MTMR2 gene encodes a protein that
is highly homologous to MTM1 [8]. In addition, we pre-
viously demonstrated that zebrafish mtmr2 functionally
compensates (at least in part) for loss of mtm1, sug-
gesting that MTMR2 and MTM1 are functionally quite
similar [37]. However, in contrast to our findings in
Mtm1-null mice, Bolino and colleagues found that plt
haploinsufficiency rescued neuropathy in Mtmr2-knock-
out animals [30]. The reasons why reduction of FIG4
levels improved the MTMR2-related neuropathology,
but not the muscle pathology, seen in Mtm1-null mice
are not clear. This distinction may provide another indi-
cation of the nonessential role of FIG4 in skeletal muscle
or may reflect different quantitative requirements for PI
(3,5)P2 in neurons and muscle or specific differences be-
tween mammalian MTMR2 and MTM1.
Conclusions
We present data demonstrating that FIG4 is required for
muscle function but is dispensable for muscle develop-
ment. In addition, most abnormalities associated with Fig4
mutation appears to be secondary to the severe neuropathy
documented in plt mice. Our results do not support a role
for FIG4 in EC coupling. Future experiments are needed to
more firmly establish the relationship between PI(3,5)P2
and EC coupling.
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